Want to see TCRT full AI Analyst Report?
Alaunos Therapeutics (TCRT) AI Stock Analysis
Alaunos Therapeutics
(NASDAQ:TCRT)
Alaunos Therapeutics' overall score is primarily impacted by its weak financial performance with ongoing losses and negative cash flows. While the technical analysis shows some positive momentum, the negative P/E ratio and lack of dividends underscore valuation challenges. The absence of earnings call and corporate events information further limits the stock’s appeal.
Alaunos Therapeutics (TCRT) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $5.71M
- Dividend Yield
- ―
- Average Volume (3M)
- 7.50M
- Price to Earnings (P/E)
- -1.0
- Beta (1Y)
- -2.97
- Revenue Growth
- -50.00%
- EPS Growth
- 20.95%
- Country
- US
- Employees
- 1
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Alaunos Therapeutics Business Overview & Revenue Model
Company Description
Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies. Their pipeline includes a TCR Library, currently undergoing Phase I/II clinical trials...
How the Company Makes Money
Alaunos Therapeutics generates revenue primarily through the development and commercialization of its TCR-based therapies. The company may earn income through collaboration agreements, research and development partnerships, and potential licensing de...
Alaunos Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TCRT, the sentiment is Neutral. The current price of 1.95 is below the 20-day moving average (MA) of 1.98, above the 50-day MA of 1.64, and below the 200-day MA of 2.33, indicating a neutral trend. The MACD of 0.20 indicates Positive momentum. The RSI at 50.03 is Neutral, neither overbought nor oversold. The STOCH value of 11.31 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TCRT.
Alaunos Therapeutics Risk Analysis
Alaunos Therapeutics disclosed 40 risk factors in its most recent earnings report. Alaunos Therapeutics reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
1 New RiskAlaunos Therapeutics Peers Comparison
Overall Rating
GRI58Neutral- TCRT45Neutral
CLDI41Neutral
AIM40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| GRI | 58Neutral | $3.34M | -0.04 | -134.03% | ― | ― | 93.96% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TCRT | 45Neutral | $7.05M | -1.00 | -232.60% | ― | -50.00% | 20.95% |
| CLDI | 41Neutral | $2.53M | -0.01 | -372.86% | ― | ― | 53.95% |
| AIM | 40Underperform | $6.16M | -0.04 | 952.76% | ― | -21.49% | 84.62% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TCRT | Alaunos Therapeutics Inc | 1.95 | -0.76 | -28.04% | |
| AIM | Aim Immunotech Inc. | 0.15 | -1.85 | -92.33% | |
| GRI | Gri Bio, Inc. | 1.53 | -43.27 | -96.58% | |
| CLDI | Calidi Biotherapeutics, Inc. | 0.69 | -23.79 | -97.19% |
Alaunos Therapeutics Corporate Events
Alaunos Therapeutics Reaches Settlement With MD Anderson Cancer
PositiveOn December 17, 2025, Alaunos Therapeutics, Inc. entered into a Settlement and Release Agreement with The University of Texas M.D. Anderson Cancer Center to resolve disputes over unpaid invoices tied to a 2019 research and development agreement. Alau...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: May 03, 2025